ERBB2 and breast carcinoma: Lapatinib is currently employed in combination with capecitabine [18] to treat patients with advanced HER2-positive breast cancer following standard therapy with anthracyclines and taxanes or in combination with trastuzumab for patients with metastatic HER2-positive in prior chemotherapy [19].